<p>(A) Sequence and position of the consensus FHRE sequence on the EXO1 promoter. (B) ChIP assays were done in A2780 and SKOV3 cells. Chromatin fragments of the cells were immunoprecipitated with anti-FOXM1 antibody and negative control IgG and subjected to PCR. 1% of the total cell lysates were subjected to PCR before immunoprecipitation as inputs. (C) Schematic structure of wild-type (WT) and mutant (Mut) forms of FHRE2-containing promoter reporters. (D) Luciferase activity with or without mutation in EXO1 promoter. A2780 and SKOV3 cells were transfected with wild-type or mutant FRHE2-containing reporter, or co-transfected with FOXM1 siRNA and wild-type reporter (pGL-3-Basic and pGL3-EXO1 were used as negative and positive control, respec...
<p><b>(A)</b> Scheme of the cDNA construct containing a FOXC1-binding element present in the <i>CXCR...
<p>(A) Luciferase (luc) reporter vectors consisting of the human (h) or mouse (m) <i>MSX2</i> promot...
<p>(A) A2780 and SKOV3 cells were treated with the indicated concentration of cisplatin for 24 h. Af...
<p>A2780 and SKOV3 cells were transfected with EXO1 specific siRNA or NC siRNA. (A)The expression of...
<p>(A) FOXM1 binding to CDC25A promoter was confirmed by ChIP-qPCR. Primer set A was designed to spa...
<p>A2780 and SKOV3 cells were treated with the indicated concentration of cisplatin for 24-time PCR ...
<div><p>(A) Diagram of the Twist 1-binding site in the human FoxM1 promoter (1kb) and two FoxM1 luci...
<p><b>A,</b> transactivation of the Anxa1 promoter in SW1088-FoxM1 cells (left) and repression of th...
<p><b>(A)</b> Schematic of a potential FOXM1 binding site in the <i>AGR2</i> promoter (left panel). ...
<p><b>A</b>, Sequence and position of putative FoxQ1 binding sites on the NRXN3 promoter. <b>B</b>, ...
<div><p>Cisplatin is commonly used in ovarian cancer chemotherapy, however, chemoresistance to cispl...
Cisplatin is commonly used in ovarian cancer chemotherapy, however, chemoresistance to cisplatin rem...
Immunoblotting analyses were performed with the indicated antibodies. (A) SK-Hep1 cells were stably ...
<p>(A) Schematic diagram of CDC25A promoter showing the 3′ distal end containing two E2F binding sit...
Cisplatin is commonly used in ovarian cancer chemotherapy, however, chemoresistance to cisplatin rem...
<p><b>(A)</b> Scheme of the cDNA construct containing a FOXC1-binding element present in the <i>CXCR...
<p>(A) Luciferase (luc) reporter vectors consisting of the human (h) or mouse (m) <i>MSX2</i> promot...
<p>(A) A2780 and SKOV3 cells were treated with the indicated concentration of cisplatin for 24 h. Af...
<p>A2780 and SKOV3 cells were transfected with EXO1 specific siRNA or NC siRNA. (A)The expression of...
<p>(A) FOXM1 binding to CDC25A promoter was confirmed by ChIP-qPCR. Primer set A was designed to spa...
<p>A2780 and SKOV3 cells were treated with the indicated concentration of cisplatin for 24-time PCR ...
<div><p>(A) Diagram of the Twist 1-binding site in the human FoxM1 promoter (1kb) and two FoxM1 luci...
<p><b>A,</b> transactivation of the Anxa1 promoter in SW1088-FoxM1 cells (left) and repression of th...
<p><b>(A)</b> Schematic of a potential FOXM1 binding site in the <i>AGR2</i> promoter (left panel). ...
<p><b>A</b>, Sequence and position of putative FoxQ1 binding sites on the NRXN3 promoter. <b>B</b>, ...
<div><p>Cisplatin is commonly used in ovarian cancer chemotherapy, however, chemoresistance to cispl...
Cisplatin is commonly used in ovarian cancer chemotherapy, however, chemoresistance to cisplatin rem...
Immunoblotting analyses were performed with the indicated antibodies. (A) SK-Hep1 cells were stably ...
<p>(A) Schematic diagram of CDC25A promoter showing the 3′ distal end containing two E2F binding sit...
Cisplatin is commonly used in ovarian cancer chemotherapy, however, chemoresistance to cisplatin rem...
<p><b>(A)</b> Scheme of the cDNA construct containing a FOXC1-binding element present in the <i>CXCR...
<p>(A) Luciferase (luc) reporter vectors consisting of the human (h) or mouse (m) <i>MSX2</i> promot...
<p>(A) A2780 and SKOV3 cells were treated with the indicated concentration of cisplatin for 24 h. Af...